Bay Area Biotech Investor

A Valuation Model For Endocyte's Small Molecule Drug Conjugates And Imaging Platform

Endocyte (NASDAQ:ECYT) is a biopharmaceutical company targeting cancer with a unique small molecule drug conjugate (SMDC) and companion imaging platform. Despite the stock price rising to an all time high last week, Endocyte is still undervalued. To provide you with sufficient background information, I suggest you read my previous article on Endocyte before reading my valuation model presented in this article. The purpose of this article is to determine the present value of Endocyte using discounted cash flow (DCF) analysis. Although Endocyte has multiple programs in clinical development, I will only discuss the most advanced: vintafolide (EC145)/etarfolatide (EC20) [currently in a phase III clinical trial (PROCEED) for platinum resistant ovarian cancer (PROC) and a phase II clinical trial...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details